Glioblastoma and meningioma biology: targeted therapy and oncolytic virus therapy

Fares Nigim

doi:10.26481/dis.20191220fn

Glioblastoma and meningioma biology: targeted therapy and oncolytic virus therapy

Fares Nigim

Research output: Thesis › Doctoral Thesis › External prepared

Abstract

In my PhD research I tackled a number of projects and this included: a new glioblastoma model with palisading necrosis, hypervascularity, and hypoxia, and treatment with HIF-1a inhibitor digoxin; a patient-derived malignant meningioma model that is tumorigenic in immune-deficient mice treated with oncolytic herpes simplex virus; targeting high grade meningioma with a b1 integrin antagonizing antibody; studied TGF-beta pathway in a multiple glioblastoma models and combined antagonists of TGF-beta pathway with oncolytic herpes simplex virus; and studied AS1411, the first oligodeoxynucleotide aptamer to reach clinical trials in many cancers, and found the mechanism by which it inhibits the growth of glioma cells and improve survival of mice bearing glioblastoma. Finally, I bridged all of my experimental work with introduction, discussion and conclusion as well as a review on novel therapies for meningiomas.

Original language	English
Awarding Institution	Maastricht University
Supervisors/Advisors	Temel, Yasin, Supervisor Rabkin, S.D., Supervisor, External person Wakimoto, Hiroaki, Co-Supervisor, External person Ackermans, Linda, Co-Supervisor
Award date	20 Dec 2019
DOIs	https://doi.org/10.26481/dis.20191220fn
Publication status	Published - 2019

Keywords

Cancer Biology
Brain Cancer
Targeted Therapy
Oncolytic Virus Therapy
Preclinical Cancer Animal Models
Cutting Edge Cancer Treatment

Access to Document

10.26481/dis.20191220fn

Cite this

@phdthesis{c81d688d9d4d4848b4efeaeddacf6da1,

title = "Glioblastoma and meningioma biology: targeted therapy and oncolytic virus therapy",

abstract = "In my PhD research I tackled a number of projects and this included: a new glioblastoma model with palisading necrosis, hypervascularity, and hypoxia, and treatment with HIF-1a inhibitor digoxin; a patient-derived malignant meningioma model that is tumorigenic in immune-deficient mice treated with oncolytic herpes simplex virus; targeting high grade meningioma with a b1 integrin antagonizing antibody; studied TGF-beta pathway in a multiple glioblastoma models and combined antagonists of TGF-beta pathway with oncolytic herpes simplex virus; and studied AS1411, the first oligodeoxynucleotide aptamer to reach clinical trials in many cancers, and found the mechanism by which it inhibits the growth of glioma cells and improve survival of mice bearing glioblastoma. Finally, I bridged all of my experimental work with introduction, discussion and conclusion as well as a review on novel therapies for meningiomas.",

keywords = "Cancer Biology, Brain Cancer, Targeted Therapy, Oncolytic Virus Therapy, Preclinical Cancer Animal Models, Cutting Edge Cancer Treatment",

author = "Fares Nigim",

year = "2019",

doi = "10.26481/dis.20191220fn",

language = "English",

school = "Maastricht University",

}

TY - BOOK

T1 - Glioblastoma and meningioma biology

T2 - targeted therapy and oncolytic virus therapy

AU - Nigim, Fares

PY - 2019

Y1 - 2019

N2 - In my PhD research I tackled a number of projects and this included: a new glioblastoma model with palisading necrosis, hypervascularity, and hypoxia, and treatment with HIF-1a inhibitor digoxin; a patient-derived malignant meningioma model that is tumorigenic in immune-deficient mice treated with oncolytic herpes simplex virus; targeting high grade meningioma with a b1 integrin antagonizing antibody; studied TGF-beta pathway in a multiple glioblastoma models and combined antagonists of TGF-beta pathway with oncolytic herpes simplex virus; and studied AS1411, the first oligodeoxynucleotide aptamer to reach clinical trials in many cancers, and found the mechanism by which it inhibits the growth of glioma cells and improve survival of mice bearing glioblastoma. Finally, I bridged all of my experimental work with introduction, discussion and conclusion as well as a review on novel therapies for meningiomas.

AB - In my PhD research I tackled a number of projects and this included: a new glioblastoma model with palisading necrosis, hypervascularity, and hypoxia, and treatment with HIF-1a inhibitor digoxin; a patient-derived malignant meningioma model that is tumorigenic in immune-deficient mice treated with oncolytic herpes simplex virus; targeting high grade meningioma with a b1 integrin antagonizing antibody; studied TGF-beta pathway in a multiple glioblastoma models and combined antagonists of TGF-beta pathway with oncolytic herpes simplex virus; and studied AS1411, the first oligodeoxynucleotide aptamer to reach clinical trials in many cancers, and found the mechanism by which it inhibits the growth of glioma cells and improve survival of mice bearing glioblastoma. Finally, I bridged all of my experimental work with introduction, discussion and conclusion as well as a review on novel therapies for meningiomas.

KW - Cancer Biology

KW - Brain Cancer

KW - Targeted Therapy

KW - Oncolytic Virus Therapy

KW - Preclinical Cancer Animal Models

KW - Cutting Edge Cancer Treatment

U2 - 10.26481/dis.20191220fn

DO - 10.26481/dis.20191220fn

M3 - Doctoral Thesis

ER -

Glioblastoma and meningioma biology: targeted therapy and oncolytic virus therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this